These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 20627323)
1. [B-cell-depletion therapy in systemic autoinmune diseases. Recommendations for use in clinical practice]. Ramos-Casals M; Díaz-Lagares C; Khamashta MA; Med Clin (Barc); 2011 Mar; 136(6):257-63. PubMed ID: 20627323 [No Abstract] [Full Text] [Related]
2. Rituximab and its use in autoimmune bullous disorders. Daniel BS; Murrell DF; Joly P Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000 [TBL] [Abstract][Full Text] [Related]
3. Rituximab and its use in autoimmune bullous disorders. Daniel BS; Murrell DF; Joly P Immunol Allergy Clin North Am; 2012 May; 32(2):331-7, viii. PubMed ID: 22560146 [TBL] [Abstract][Full Text] [Related]
4. Treating human autoimmune disease by depleting B cells. Looney RJ Ann Rheum Dis; 2002 Oct; 61(10):863-6. PubMed ID: 12228152 [No Abstract] [Full Text] [Related]
5. [Rationale and clinical evidence for the use of rituximab in glomerular diseases]. Mani LY; Vogt B; Burnier M; Golshayan D Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313 [TBL] [Abstract][Full Text] [Related]
6. An antibody treats almost all refractory autoimmune diseases: fact and beyond. Lin LY; Hsu MH; Yang KD J Formos Med Assoc; 2012 Apr; 111(4):181-2. PubMed ID: 22655322 [No Abstract] [Full Text] [Related]
7. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Shetty S; Ahmed AR Autoimmunity; 2013 Dec; 46(8):487-96. PubMed ID: 24151854 [TBL] [Abstract][Full Text] [Related]
14. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836 [TBL] [Abstract][Full Text] [Related]
15. Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy. Nielsen JF; El Fassi D; Nielsen CH; Hegedüs L; Lauer SA; Silkiss RZ; Prause JU Acta Ophthalmol; 2009 Nov; 87(8):927-9. PubMed ID: 19785644 [No Abstract] [Full Text] [Related]
16. B cell depletion in autoimmune disease. Gorman C; Leandro M; Isenberg D Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S17-21. PubMed ID: 15180893 [TBL] [Abstract][Full Text] [Related]
17. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Tesfa D; Ajeganova S; Hägglund H; Sander B; Fadeel B; Hafström I; Palmblad J Arthritis Rheum; 2011 Aug; 63(8):2209-14. PubMed ID: 21560117 [TBL] [Abstract][Full Text] [Related]
18. Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. Yi JS; Decroos EC; Sanders DB; Weinhold KJ; Guptill JT Muscle Nerve; 2013 Dec; 48(6):992-3. PubMed ID: 24006142 [No Abstract] [Full Text] [Related]
19. Rituximab treatment for vasculitis. Jayne D Clin J Am Soc Nephrol; 2010 Aug; 5(8):1359-62. PubMed ID: 20671223 [No Abstract] [Full Text] [Related]
20. [Autoimmune pancreatitis -- rituximab for the prevention of relapses?]. Lichert F Z Gastroenterol; 2014 Mar; 52(3):248. PubMed ID: 24761439 [No Abstract] [Full Text] [Related] [Next] [New Search]